Literature DB >> 29723766

Timing and risk of mood disorders requiring psychotropics in long-term survivors of adult cancers: A nationwide cohort study.

Wen-Kuan Huang1, Yeong-Yuh Juang2, Chia-Chi Chung3, Shu-Hao Chang3, John Wen-Cheng Chang4, Yung-Chang Lin4, Hung-Ming Wang4, Hsien-Kun Chang4, Jen-Shi Chen4, Chieh-Sheng Tsai5, Kuang-Hui Yu6, Chang-Fu Kuo6, Lai-Chu See7.   

Abstract

BACKGROUND: The increasing number of long-term cancer survivors over the past few decades poses the challenge of mental health care needs. However, little is known about risks of mood disorders in long-term cancer survivors.
METHODS: Long-term survivors (≥5 years) of adult cancers (LSAC) (n = 190,748) newly diagnosed between January 1, 2000 and December 31, 2007 were matched with one control. The primary outcome was diagnosis of mood disorders requiring psychotropics. Cumulative incidences and sub-hazard ratios (SHR) were calculated and multivariate analyses were conducted after accounting for mortality.
RESULTS: The mood disorder risk was significantly higher in the LSAC cohort than in the control cohort (adjusted SHR = 1.16, 95% confidence interval [CI] = 1.13-1.18, P < 0.001). Patients with certain cancer types were at increased risk, particularly in the first 2 years after diagnosis. However, patients with head and neck cancers or esophageal cancers had a higher risk after the 5-year follow-up period. Multivariate analysis indicated that being female, aged 40-59 years, with more than two primary cancers, receiving two or more treatment modalities, having CCI scores higher than 3, a higher urbanization level, and lower monthly income were independently associated with an increased risk of mood disorders. LIMITATIONS: Some potential confounders such as lifestyle factors were not available in the study.
CONCLUSION: These findings call for increased mental health awareness not only in the early years after the cancer diagnosis, but also during long-term follow-up for certain cancer subtypes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult cancer survivor; Cohort study; Depression; Mood disorder; Psychotropics

Mesh:

Substances:

Year:  2018        PMID: 29723766     DOI: 10.1016/j.jad.2018.04.107

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  1 in total

1.  Clinical observation on the benefits of antidepressant intervention in advanced cancer patients.

Authors:  Bing Pu; Ning Wang; Chuansheng Wang; Bo Sun
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.